31.39
price up icon2.82%   0.86
after-market アフターアワーズ: 31.39
loading
前日終値:
$30.53
開ける:
$30.89
24時間の取引高:
854.32K
Relative Volume:
0.93
時価総額:
$2.76B
収益:
$218.71M
当期純損益:
$-113.70M
株価収益率:
-24.08
EPS:
-1.3034
ネットキャッシュフロー:
$-73.47M
1週間 パフォーマンス:
-5.76%
1か月 パフォーマンス:
-0.88%
6か月 パフォーマンス:
+22.19%
1年 パフォーマンス:
+74.29%
1日の値動き範囲:
Value
$30.84
$31.76
1週間の範囲:
Value
$29.57
$33.51
52週間の値動き範囲:
Value
$13.45
$39.28

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Name
名前
Ideaya Biosciences Inc
Name
セクター
Healthcare (1114)
Name
電話
650-443-6209
Name
住所
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
職員
145
Name
Twitter
Name
次回の収益日
2026-02-13
Name
最新のSEC提出書
Name
IDYA's Discussions on Twitter

Compare IDYA vs VRTX, REGN, ALNY, ARGX, INSM

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IDYA icon
IDYA
Ideaya Biosciences Inc
31.39 2.68B 218.71M -113.70M -73.47M -1.3034
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 113.96B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 78.41B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 40.85B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 42.05B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 29.99B 606.42M -1.28B -997.58M -6.403

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-07 再開されました UBS Buy
2025-11-24 開始されました Truist Buy
2025-09-18 開始されました Guggenheim Buy
2025-09-04 開始されました Barclays Overweight
2025-09-04 開始されました Citizens JMP Mkt Outperform
2025-07-22 開始されました TD Cowen Buy
2025-07-10 再開されました Goldman Neutral
2025-06-26 開始されました Wells Fargo Overweight
2024-11-18 開始されました Stephens Overweight
2024-11-05 ダウングレード Leerink Partners Outperform → Market Perform
2024-10-24 開始されました UBS Buy
2024-10-15 開始されました Cantor Fitzgerald Overweight
2024-07-08 開始されました Mizuho Outperform
2024-03-08 開始されました BTIG Research Buy
2023-08-08 開始されました SVB Securities Outperform
2023-05-24 開始されました Goldman Buy
2023-04-24 アップグレード Stifel Hold → Buy
2023-03-23 開始されました Berenberg Buy
2023-02-28 開始されました RBC Capital Mkts Outperform
2022-12-28 開始されました CapitalOne Overweight
2022-10-27 開始されました Citigroup Buy
2022-08-15 ダウングレード Stifel Buy → Hold
2022-07-18 再開されました Oppenheimer Outperform
2022-03-10 アップグレード Stifel Hold → Buy
2021-09-23 開始されました Stifel Hold
2021-06-04 再開されました Robert W. Baird Outperform
2021-03-11 開始されました Guggenheim Buy
2020-10-07 開始されました Wedbush Outperform
2020-09-01 開始されました Northland Capital Outperform
2020-07-13 アップグレード JP Morgan Neutral → Overweight
2020-06-17 繰り返されました H.C. Wainwright Buy
2020-04-06 開始されました H.C. Wainwright Buy
2020-03-13 開始されました ROTH Capital Buy
2019-10-17 開始されました Oppenheimer Outperform
2019-09-10 開始されました Robert W. Baird Outperform
2019-06-17 開始されました Citigroup Buy
2019-06-17 開始されました JP Morgan Neutral
2019-06-17 開始されました Jefferies Buy
すべてを表示

Ideaya Biosciences Inc (IDYA) 最新ニュース

pulisher
Mar 23, 2026

RBC Capital reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada

Mar 23, 2026
pulisher
Mar 23, 2026

Jefferies reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada

Mar 23, 2026
pulisher
Mar 23, 2026

IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.1%Here's Why - MarketBeat

Mar 23, 2026
pulisher
Mar 23, 2026

IDEAYA Biosciences Sees Unusually High Options Volume (NASDAQ:IDYA) - MarketBeat

Mar 23, 2026
pulisher
Mar 23, 2026

Ideaya Biosciences stock maintained at Outperform by Mizuho on trial timing - Investing.com Canada

Mar 23, 2026
pulisher
Mar 23, 2026

Citizens reiterates Ideaya Biosciences stock rating on mUM trial data By Investing.com - Investing.com Canada

Mar 23, 2026
pulisher
Mar 22, 2026

IDEAYA delays darovasertib trial results to mid-April By Investing.com - Investing.com Canada

Mar 22, 2026
pulisher
Mar 22, 2026

Cancer trial readout nears as IDEAYA targets first-half April lock - Stock Titan

Mar 22, 2026
pulisher
Mar 21, 2026

IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo

Mar 21, 2026
pulisher
Mar 20, 2026

IDYA Stock Price, Quote & Chart | IDEAYA BIOSCIENCES INC (NASDAQ:IDYA) - ChartMill

Mar 20, 2026
pulisher
Mar 19, 2026

(IDYA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Mar 19, 2026
pulisher
Mar 18, 2026

Barclays Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail

Mar 18, 2026
pulisher
Mar 18, 2026

IDEAYA Biosciences (IDYA) Gets a Buy from Mizuho Securities - The Globe and Mail

Mar 18, 2026
pulisher
Mar 18, 2026

IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs - Barchart.com

Mar 18, 2026
pulisher
Mar 18, 2026

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 18, 2026
pulisher
Mar 17, 2026

IDEAYA Biosciences, Inc. $IDYA Shares Purchased by Cinctive Capital Management LP - MarketBeat

Mar 17, 2026
pulisher
Mar 16, 2026

Iron Triangle Partners LP Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat

Mar 16, 2026
pulisher
Mar 15, 2026

A Look At IDEAYA Biosciences (IDYA) Valuation After IDE892 Trial Enrollment And Pipeline Refocus - simplywall.st

Mar 15, 2026
pulisher
Mar 15, 2026

IDEAYA Biosciences, Inc. $IDYA Position Increased by Baker BROS. Advisors LP - MarketBeat

Mar 15, 2026
pulisher
Mar 13, 2026

IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo

Mar 13, 2026
pulisher
Mar 12, 2026

42,283 Shares in IDEAYA Biosciences, Inc. $IDYA Bought by WINTON GROUP Ltd - MarketBeat

Mar 12, 2026
pulisher
Mar 09, 2026

Truist reiterates Ideaya Biosciences stock rating on MTAP program By Investing.com - Investing.com Canada

Mar 09, 2026
pulisher
Mar 09, 2026

IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating - TipRanks

Mar 09, 2026
pulisher
Mar 09, 2026

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update - Finviz

Mar 09, 2026
pulisher
Mar 09, 2026

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial - GuruFocus

Mar 09, 2026
pulisher
Mar 09, 2026

Ideaya Biosciences announces first-patient-in for phase 1 trial of IDE892 - marketscreener.com

Mar 09, 2026
pulisher
Mar 09, 2026

Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892 - TradingView

Mar 09, 2026
pulisher
Mar 09, 2026

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update – Company Announcement - Financial Times

Mar 09, 2026
pulisher
Mar 08, 2026

IDEAYA Biosciences announces the latest development timeline for its Cdkn2a project - Bitget

Mar 08, 2026
pulisher
Mar 08, 2026

IDYA SEC FilingsIdeaya Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 08, 2026
pulisher
Mar 08, 2026

(IDYA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Mar 08, 2026
pulisher
Mar 07, 2026

Goldman Sachs Maintains IDEAYA Biosciences (IDYA) Neutral Recommendation - MSN

Mar 07, 2026
pulisher
Mar 06, 2026

IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC - finance.yahoo.com

Mar 06, 2026
pulisher
Mar 06, 2026

Aug Mood: What is IDEAYA Biosciences Incs P E ratio telling usJuly 2025 Action & Fast Gain Stock Tips - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 04, 2026

Fisher Asset Management LLC Lowers Stock Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat

Mar 04, 2026
pulisher
Mar 03, 2026

IDYA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up on Insider Buying Activity - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: A Biotech Gem With 51% Upside Potential - DirectorsTalk Interviews

Mar 03, 2026
pulisher
Mar 03, 2026

Did IDEAYA’s (IDYA) First-in-Human IDE034 Trial Just Redefine Its Targeted Oncology Strategy? - simplywall.st

Mar 03, 2026
pulisher
Mar 03, 2026

Ideaya Biosciences Insider Bought Shares Worth $1,647,890, According to a Recent SEC Filing - marketscreener.com

Mar 03, 2026
pulisher
Mar 02, 2026

Insider Buying: IDEAYA Biosciences (NASDAQ:IDYA) Director Buys 50,000 Shares of Stock - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

Ideaya Biosciences (IDYA) director Stein buys $1.65 million in stock By Investing.com - Investing.com Australia

Mar 02, 2026
pulisher
Mar 02, 2026

Ideaya Biosciences (IDYA) director Stein buys $1.65 million in stock - Investing.com

Mar 02, 2026
pulisher
Mar 02, 2026

Director Jeffrey Stein buys 50,000 IDEAYA Biosciences (IDYA) shares in market - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

IDEAYA Biosciences Director Jeffrey Stein Acquires 50,000 Shares - TradingView

Mar 02, 2026
pulisher
Mar 02, 2026

IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - The AI Journal

Mar 02, 2026
pulisher
Feb 28, 2026

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 - Via TT

Feb 28, 2026
pulisher
Feb 28, 2026

Assessing IDEAYA Biosciences (IDYA) Valuation After IDE034 First-In-Human Dosing Milestone - Yahoo Finance

Feb 28, 2026
pulisher
Feb 27, 2026

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 - lelezard.com

Feb 27, 2026
pulisher
Feb 27, 2026

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 – News Hub - Medianet News Hub

Feb 27, 2026

Ideaya Biosciences Inc (IDYA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
大文字化:     |  ボリューム (24 時間):